• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Perrigo Secures API Divestiture for $110M

contractpharmNovember 22, 2017

Tag: Perrigo , API

Perrigo Company has completed the divestiture of its active pharmaceutical ingredient (API) business based in Israel to SK Capital for $110 million. The company is also one of the world's largest manufacturers of over-the-counter (OTC) healthcare products and suppliers of infant formulas.

"Actions taken as part of this review process have enabled us to simplify, focus and execute on our core businesses. We continue to look at capital deployment opportunities that drive value for shareholders and further our mission of providing quality, affordable healthcare products to consumers around the globe," said Perrigo's chief executive officer, John T. 

Previous:Tiny Corbus Aims to Have Four Drugs in Mid- to Late-Stage Development by Next Year

Next:FDA approves first two-drug regimen for certain patients with HIV

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Perrigo Secures API Divestiture for $110M | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Toradol USP ≥98.5% API Pharmaceutical made in china

Toradol USP ≥98.5% API Pharmaceutical made in china
Sulfaguanidine EP Pharmaceutical Sulfanilamide supplier API made in china

Sulfaguanidine EP Pharmaceutical Sulfanilamide supplier API made in china
API production

API production
Rapid moisture analyzer

Rapid moisture analyzer
Urapidil 99%min Pharmaceutical API Hypertension drugs made in china

Urapidil 99%min Pharmaceutical API Hypertension drugs made in china
Pharmaceutical Grade Apremilast API CAS 608141-41-9

Pharmaceutical Grade Apremilast API CAS 608141-41-9
Chamomile Flower Extract 1% 1.2% 1.6% Apigenin 98% Anti Cancer

Chamomile Flower Extract 1% 1.2% 1.6% Apigenin 98% Anti Cancer
Olanzapine

Olanzapine
Betamethasone Dipropionate USP ≥97.0% Hormone API made in china

Betamethasone Dipropionate USP ≥97.0% Hormone API made in china
Faropenem sodium hemipentahydrate 98%min supplier Pharmaceutical API Antibiotics made in china

Faropenem sodium hemipentahydrate 98%min supplier Pharmaceutical API Antibiotics made in china

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service